Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

Not specified

Study Completion Date

November 30, 1994

Conditions
HIV InfectionsHistoplasmosis
Interventions
DRUG

Fluconazole

Trial Locations (23)

10003

Beth Israel Med Ctr, New York

10021

Cornell Univ Med Ctr, New York

10025

Saint Luke's - Roosevelt Hosp Ctr, New York

10029

Mount Sinai Med Ctr, New York

10461

Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, The Bronx

Montefiore Family Health Ctr / Bronx Municipal Hosp, The Bronx

Samaritan Village Inc / Bronx Municipal Hosp, The Bronx

10467

Montefiore Med Ctr / Bronx Municipal Hosp, The Bronx

North Central Bronx Hosp / Bronx Municipal Hosp, The Bronx

29169

Julio Arroyo, West Columbia

35294

Univ of Alabama at Birmingham, Birmingham

46202

Methodist Hosp of Indiana / Life Care Clinic, Indianapolis

63112

St Louis Regional Hosp / St Louis Regional Med Ctr, St Louis

64132

Infectious Diseases Association / Research Med Ctr, Kansas City

77030

Houston Veterans Administration Med Ctr, Houston

Univ TX Health Science Ctr, Houston

94121

San Francisco Veterans Administration Med Ctr, San Francisco

432101228

Ohio State Univ Hosp Clinic, Columbus

462025250

Indiana Univ Hosp, Indianapolis

641082792

Univ of Missouri at Kansas City School of Medicine, Kansas City

900331079

Univ of Southern California / LA County USC Med Ctr, Los Angeles

01199

Baystate Med Ctr of Springfield, Springfield

01605

Worcester Memorial Hosp / Med Ctr of Cntrl MA-Memorial, Worcester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000627 - Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome | Biotech Hunter | Biotech Hunter